PURPOSE: The 20-year survival rates are unknown for the majority of melanoma patients-those with thin melanomas. We determined 20-year survival rates of patients diagnosed with thin melanomas (≤ 1.00 mm) in the general population and also determined the main prognostic factors. PATIENTS AND METHODS: Available clinical and histologic data from the Queensland Cancer Registry were obtained for all patients diagnosed with a single thin invasive melanoma from 1982 to 2006 and matched against national death registration data. Melanoma-specific survival estimates to December 31, 2007, were assessed, and subgroup differences in prognosis were determined by fitting multivariate Cox proportional hazard models. RESULTS: Among 26,736 people in the state of Queensland diagnosed with thin melanomas, the 20-year survival was 96%. The most influential determinants of prognosis were tumor thickness ≥ 0.75 mm (adjusted hazard ratio [HR], 4.33; 95% CI, 2.8 to 6.8 compared with tumors < 0.25 mm) and patient age at diagnosis older than 65 years (HR, 2.8; 95% CI, 1.8 to 4.5) compared with age younger than 25 years. Acral lentiginous and nodular tumors, male sex, tumor site on the scalp or neck, or tumor invasion of the entire papillary dermis each independently increased the risk of dying from thin invasive melanoma. CONCLUSION: The outlook for patients with thin invasive melanoma is positive, although continued clinical vigilance is warranted for patients with nodular melanoma and those with the thickest tumors.
PURPOSE: The 20-year survival rates are unknown for the majority of melanomapatients-those with thin melanomas. We determined 20-year survival rates of patients diagnosed with thin melanomas (≤ 1.00 mm) in the general population and also determined the main prognostic factors. PATIENTS AND METHODS: Available clinical and histologic data from the Queensland Cancer Registry were obtained for all patients diagnosed with a single thin invasive melanoma from 1982 to 2006 and matched against national death registration data. Melanoma-specific survival estimates to December 31, 2007, were assessed, and subgroup differences in prognosis were determined by fitting multivariate Cox proportional hazard models. RESULTS: Among 26,736 people in the state of Queensland diagnosed with thin melanomas, the 20-year survival was 96%. The most influential determinants of prognosis were tumor thickness ≥ 0.75 mm (adjusted hazard ratio [HR], 4.33; 95% CI, 2.8 to 6.8 compared with tumors < 0.25 mm) and patient age at diagnosis older than 65 years (HR, 2.8; 95% CI, 1.8 to 4.5) compared with age younger than 25 years. Acral lentiginous and nodular tumors, male sex, tumor site on the scalp or neck, or tumor invasion of the entire papillary dermis each independently increased the risk of dying from thin invasive melanoma. CONCLUSION: The outlook for patients with thin invasive melanoma is positive, although continued clinical vigilance is warranted for patients with nodular melanoma and those with the thickest tumors.
Authors: K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan Journal: Ir J Med Sci Date: 2014-11-01 Impact factor: 1.568
Authors: Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry Journal: J Invest Dermatol Date: 2016-06-25 Impact factor: 8.551
Authors: Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Pamela A Groben; Eloise Parrish; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Lynn From; Klaus J Busam; Honglin Hao; Irene Orlow; Peter A Kanetsky; Li Luo; Anne S Reiner; Susan Paine; Jill S Frank; Jennifer I Bramson; Lorraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway Journal: JAMA Oncol Date: 2015-06 Impact factor: 31.777
Authors: Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Michael A Marchetti; Daniel G Coit; Stephen W Dusza; Ashley Yu; LaToya McLean; Yinin Hu; Japbani K Nanda; Konstantina Matsoukas; Silvia E Mancebo; Edmund K Bartlett Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282